<?xml version="1.0" encoding="UTF-8"?> <rss
version="2.0"
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
xmlns:atom="http://www.w3.org/2005/Atom"
xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
> <channel><title>Medimise.com &#187; GSK</title> <atom:link href="http://www.medimise.com/tag/gsk/feed" rel="self" type="application/rss+xml" /><link>http://www.medimise.com</link> <description>Health and Medical News</description> <lastBuildDate>Thu, 19 Jan 2012 21:20:04 +0000</lastBuildDate> <language>en</language> <sy:updatePeriod>hourly</sy:updatePeriod> <sy:updateFrequency>1</sy:updateFrequency> <item><title>Anti-Smoking Vaccine Coming Soon &#8211; NicVAX</title><link>http://www.medimise.com/respiratory-health/smoking/anti-smoking-vaccine-coming-soon-nicvax</link> <comments>http://www.medimise.com/respiratory-health/smoking/anti-smoking-vaccine-coming-soon-nicvax#comments</comments> <pubDate>Wed, 18 Nov 2009 20:52:14 +0000</pubDate> <dc:creator>Medimise</dc:creator> <category><![CDATA[Smoking]]></category> <category><![CDATA[GSK]]></category> <category><![CDATA[Nabi]]></category> <category><![CDATA[NicVAX]]></category> <category><![CDATA[quit smoking]]></category> <guid
isPermaLink="false">http://www.medimise.com/?p=585</guid> <description><![CDATA[TweetIf you have tried and failed to quit smoking in the past, then there may soon be a solution &#8211; get vaccinated. A recent deal between pharmaceutical giants GlaxoSmithKline and Nabi Pharmaceuticals means that there is a strong chance that NicVAX, a quit smoking drug that was developed by Nabi may soon make it to market. No doubt there is some further testing to be carried out first. GlaxoSmithKline Biologicals SA (GSK) and Nabi Biopharmaceuticals (Nabi) today announced an exclusive worldwide option and licensing agreement for a nicotine conjugate candidate vaccine (NicVAX(R)), an investigational vaccine for the treatment of nicotine addiction and the prevention of smoking relapse, as well as for the development of a second generation nicotine vaccine. Under the terms of the agreement GSK will pay to Nabi an upfront non-refundable fee of $40 million at closing and will receive an option to exclusively in-license NicVAX on a worldwide basis and a license to develop follow-on next-generation nicotine vaccines using Nabi&#8217;s intellectual property. Together with the upfront payment, Nabi is eligible to receive over $500 million in option fees and regulatory, development and sales milestones for NicVAX and follow-on nicotine vaccines. Nabi will also receive double-digit royalties on [...]]]></description> <wfw:commentRss>http://www.medimise.com/respiratory-health/smoking/anti-smoking-vaccine-coming-soon-nicvax/feed</wfw:commentRss> <slash:comments>0</slash:comments> </item> </channel> </rss>
